Evidence map›Paper›PMID 32173279›Full record

ArticleClinical colorectal cancer2020

Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma.

Santiago Avila, George J Chang, N Arvind Dasari, Danyal A Smani, Prajnan Das, Joeseph M Herman, Eugene Koay, Albert Koong, Sunil Krishnan, Bruce D Minsky and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical colorectal cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Santiago AvilaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
George J ChangDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
N Arvind DasariDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Danyal A SmaniDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Prajnan DasDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Joeseph M HermanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Eugene KoayDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Albert KoongDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sunil KrishnanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Bruce D MinskyDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Grace L SmithDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Cullen TaniguchiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Melissa W TaggartDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Harmeet KaurDepartment of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Emma B HollidayDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: ebholliday@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Economic Strain and Resilience in Cancer Patients: Assessing Patient-Reported Measures of the Burdens of TreatmentK07CA211804 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SMITH, GRACE · 2016 to 2020
$853k
NCI NIH HHS K07 CA211804NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundThe role of neoadjuvant short-course radiation therapy (SCRT) in treating rectal adenocarcinoma is a topic of ongoing debate. Growing interest in total neoadjuvant therapy has spurred discussion on the optimal sequence of preoperative SCRT and chemotherapy. PATIENTS AND

methodsAll patients receiving SCRT (5 Gy × 5 fractions) were identified. Details about preoperative treatments, radiation toxicities, and postoperative complications were collected. Patients were divided into 2 groups: those who underwent surgery within 14 days of completing SCRT and those with a longer delay. Outcomes compared included extent of pathologic response, margin-negative resection rate, acute radiation toxicities, and postoperative complications.

resultsFifty-seven patients with locally advanced or metastatic rectal cancer received SCRT between 2008 and 2018. Thirty-nine of 57 patients underwent definitive pelvic surgery with total mesorectal excision. There were no significant differences in tumor downstaging, radial margin status, or percent tumor viability between patients with immediate surgery versus delayed surgery. The delay group had higher rates of nodal downstaging (64.7% vs. 18.2%; P = .003). There were no differences in total or grade 3+ gastrointestinal radiation toxicity, postoperative complications, reoperation, readmission, and mortality between the 2 groups.

conclusionsThough not yet common in the United States, SCRT has compared favorably with long course chemoradiation in multiple trials. Moreover, it is associated with greater efficiency and less disruption to chemotherapy. Our data show similar response and toxicity outcomes between the immediate and delay groups, suggesting SCRT is well-tolerated regardless of treatment sequence. Recently completed prospective trials may reveal the optimal preoperative treatment sequence.

Indexed as

AdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMargins of ExcisionMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingPostoperative ComplicationsGastrointestinal cancersRadiation toxicityTotal mesorectal excisionTotal neoadjuvant therapyTreatment sequencing

Identifiers

PMID32173279
PMCPMC7370689
OpenAlexW3004830004

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.